Stuart Therapeutics provides acknowledged leaders in ophthalmology therapeutics growth, commercialization.
STUART, Fla., Dec. 22, 2024 /PRNewswire/ — Stuart Therapeutics introduced in the present day the appointment of Tracy Valorie and Jason Werner to the corporate’s Board of Administrators, bringing the whole variety of Board members to 5. These new Administrators will maintain the positions beforehand held by Robert O. Baratta, MD, who handed away out of the blue within the third quarter of this yr, and retired US Consultant Diane Black, RN, who just lately resigned her place on the corporate’s Board.
Tracy Valorie is a strategic enterprise marketing consultant and the proprietor of ™V Associates LLC since July 2019. Ms. Valorie has 30 years of expertise within the pharmaceutical and biotech trade. Ms. Valorie served because the senior vice chairman, basic supervisor of the U.S. pharmaceutical and surgical companies at Bausch + Lomb from July 2012 to Could 2019. Previous to becoming a member of B+L in 2012, Ms. Valorie served as business lead of ophthalmology at Pfizer Inc. (NYSE: NYSE:) the place she had world accountability for the ophthalmology manufacturers in addition to accountability for business growth of the mid-stage portfolio and long-range strategic planning. She at the moment serves as a marketing consultant or board member to a number of start-up corporations and has just lately been named to the Board of Administrators of the Glaucoma Analysis Basis (GRF). Ms. Valorie holds a Grasp of Enterprise Administration from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the College of Connecticut at Storrs, CT.
Jason Werner at the moment serves as Govt Chairman of Sightstream Biotherapeutics, a biotechnology firm centered on creating regenerative therapies in Ophthalmics and is a member of the Board of Administrators of InflammX Therapeutics. Moreover, Mr. Werner had served as a director of Alimera (NASDAQ:) since Q2 2023 previous to becoming a member of Alimera’s administration workforce in This fall 2023 and subsequently serving to lead the corporate by its current sale to ANI Pharma in This fall – 2024. Mr. Werner beforehand co-founded and served as Chief Working Officer of Eyevance Prescribed drugs from the corporate’s founding by its sale to Santen Prescribed drugs Ltd. He has additionally held a wide range of business growth roles and company technique positions at corporations similar to Solar Pharma, Nicox (EPA:) SA and Encourage Prescribed drugs, all throughout the subject of ophthalmology. Mr. Werner acquired his B.S. in enterprise administration from the College of New Hampshire.
“We’re excited concerning the alternative to convey Tracy and Jason in as members of our Board of Administrators and senior advisors to Stuart Therapeutics as we transition to our subsequent stage of growth and commercialization in ophthalmology therapeutics,” stated Eric Schlumpf, Stuart’s President and CEO. “Our workforce will profit from the profitable experiences they convey to our group. We’d additionally wish to acknowledge the contributions of our good friend and co-founder Bob Baratta, MD, and Diane Black, RN, who had been instrumental in guiding the corporate by its formative levels, and we want Diane properly in her future endeavors.”
“I’m thrilled to hitch the board of administrators at Stuart Therapeutics. The chance to contribute to such an modern biotech firm on the forefront of groundbreaking remedies is really thrilling. I sit up for collaborating with an unimaginable workforce, serving to information the corporate because it appears to make a significant influence on sufferers’ lives identified with underserved ophthalmic problems,” stated Tracy Valorie.
Jason Werner stated, “That is an thrilling time for Stuart Therapeutics with key growth and pipeline milestones on the horizon. I sit up for working alongside Tracy and Eric and the remainder of the gifted workforce to serving to guarantee these novel therapeutics make their technique to sufferers whereas maximizing shareholder worth for Stuart and its buyers.”
About Stuart Therapeutics, Inc.
Stuart Therapeutics, Inc. is a medical stage ophthalmology therapeutic growth firm, primarily based in Stuart, Florida. The corporate’s lead asset, ST-100, is within the remaining levels of its Part 3 medical trial, with a readout anticipated within the first quarter of 2025. Stuart can also be creating forefront packages in retinal illness and myopia and has a growth partnership by a license for neuroprotection in glaucoma with Glaukos Corp (NYSE:). of Aliso Viejo, California.
Media Contact:
Eric Schlumpf
President & CEO
[email protected]
206-228-2781
www.stuarttherapeutics.com
